research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
Search
for
Sort by
Research
60-90 / 551 results 
research Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research iNOS inhibits hair regeneration in obese diabetic (ob/ob) mice
iNOS contributes to hair loss in obese diabetic mice and blocking it may encourage hair growth.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research The Role of Janus Kinase Inhibitors in Dermatology
Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Age-associated inflammation inhibits epidermal stem cell function
Aging causes skin stem cells to work less effectively.
research Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
Blocking JAK-STAT signaling can lead to hair growth.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Emerging Topical and Systemic JAK Inhibitors in Dermatology
JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
research Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
Baricitinib reduces inflammation and improves cell health in premature aging cells.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
JAK inhibitors show promise for treating various skin disorders effectively and safely.